Caption Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-10,400
Closed -$741K 1543
2022
Q1
$741K Sell
10,400
-121,600
-92% -$7.91M 0.01% 1055
2021
Q4
$9.87M Buy
+132,000
New +$10.4M 0.11% 237
2020
Q4
Sell
-34,000
Closed -$1.56M 1053
2020
Q3
$1.56M Buy
34,000
+8,000
+31% +$388K 0.04% 509
2020
Q2
$1.31M Buy
+26,000
New +$1.35M 0.04% 472
2019
Q4
Sell
-22,500
Closed -$1.35M 880
2019
Q3
$1.35M Sell
22,500
-1,200
-5% -$89.1K 0.07% 319
2019
Q2
$2M Buy
+23,700
New +$2.13M 0.1% 243

Other funds holding ENTA

Caption Management's ENTA Position: Q2 2022 in Review

Caption Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2022, closing a stake of 9,000 shares — an estimated $640K sold.

Caption Management first reported a position in ENTA in Q2 2019 and held it in 5 quarters. The position peaked at $1.05M in Q3 2020. 154 funds tracked by Wall St. Rank hold ENTA as of Q2 2022.

  • Caption Management reported no remaining Enanta Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Caption Management sold 9,000 Enanta Pharmaceuticals shares in Q2 2022, an estimated $640K.
  • Caption Management first reported a position in Enanta Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Caption Management's Enanta Pharmaceuticals position peaked at $1.05M in Q3 2020.
  • 154 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2022.

Based on Caption Management's 13F filing for Q2 2022, filed 15 Aug 2022.